Amarin Corp Plc (AMRN)

[Whalatane]

Again , IMHO you are poorly informed on this particular subject and subject to false equivalence.
PCSK9's were developed for the HeFH and Ho FH lipid disorders ( very high and extremely high LDL cholesterol levels
https://www.clinicaltrialsarena.com/projects/repatha-evolocumab-treatment-heterozygous-homozygous-familial-hypercholesterolemia/

No Cardiologist IMHO is prescribing a PCSK9 instead of Vascepa ...or Vascepa instead of a PCSK9.
Dr Bhatt ( as well as my Cardiologist ) think that those on PCSK9's should also add Vascepa

NVS 's Inclisiran is 2 PCSK9 shots a year ( after the first year of 3 shots ) . Repatha ( PCSK9 ) is a sub Q shot every 2 weeks .

NVS is aiming for the Statin population ...in addition to the He FH population .
Their reasoning is that while almost Statin users would not want a PCSK9 very 2 weeks instead of a daily statin ...they may sign up for a 2 shot a year PCSK9 instead of their daily statin .
This would insure better compliance and lower LDL levels .....lower rates of MI's and strokes etc
Thats what they are trying to roll out in the UK NHS .
There are problems with this rollout as you highlighted in a previous article you linked on the subject

Kiwi